BiotechTube
Agno Pharma

Agno Pharma

San Diego, United States· Est.
agnopharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3M

Overview

Agno Pharma is a private, revenue-generating CDMO/CMO founded in 2019 and headquartered in San Diego, California. The company provides comprehensive pharmaceutical development and manufacturing services, with core expertise in API/intermediates (including HPAPI and sterile API), complex drug product formulation (especially injectables and implants), and analytical services. It supports a global clientele across the drug development lifecycle, from R&D and clinical trial material production to commercial-scale cGMP manufacturing, positioning itself as an end-to-end solution provider in a competitive outsourcing market.

Oncology

Technology Platform

Integrated CDMO platform for API development (including HPAPI and sterile API), complex drug product formulation (injectables, orals, topicals), and long-acting implant manufacturing. Utilizes technologies like hot melt extrusion, injection molding, nanomilling, and employs a Quality-by-Design approach. Supported by full analytical development and ICH stability services.

Funding History

1
Total raised:$3M
Seed$3M

Opportunities

Strong demand for specialized CDMO services in high-growth areas like oncology (HPAPI), sterile injectables, and long-acting drug implants.
The trend towards outsourcing and preference for integrated, end-to-end service providers creates a significant market opportunity.
Geographic location in San Diego provides access to a dense cluster of innovative biotech clients.

Risk Factors

Revenue is entirely dependent on client projects, creating vulnerability to pipeline failures and client attrition.
Operational risks are high due to stringent cGMP requirements, especially for complex sterile and potent compounds.
The company faces intense competition from both large global CDMOs and smaller niche players.

Competitive Landscape

Agno Pharma competes in the fragmented but competitive CDMO market. It faces competition from large, full-service CDMOs (e.g., Lonza, Catalent), specialized injectable manufacturers, and other niche players in drug delivery and implants. Its differentiation is based on its integrated end-to-end services within specific complex technical niches like sterile HPAPI and long-acting implants.

More companies in Small Molecule Drugs →More companies in United States →